


Claims:

1. Form B of seletalisib, represented by formula (IA):



5

wherein n is at least about 0.1 and no more than about 2.1.

2. Form B of seletalisib as claimed in claim 1, wherein n is at least about 0.9 and
10 no more than about 2.1.

3. Form B of seletalisib as claimed in claim 1, wherein n is approximately 1.0.

4. Form B of seletalisib as claimed in claim 1, wherein n is approximately 2.0.
15

5. Form B of seletalisib as claimed in any one of the preceding claims, having an XRPD pattern that exhibits characteristic peaks at 11.0° to 11.1°, 12.5° to 12.6°, 20.9° to 21.1°, and 22.9° to 23.0° $2\theta \pm 0.2^\circ 2\theta$ using Cu K α radiation.

- 20 6. Form B of seletalisib as claimed in any one of the preceding claims, that exhibits an endothermic event at $146^\circ\text{C} \pm 6^\circ\text{C}$ in the DSC thermogram.


7. Form F of seletalisib, wherein Form F is an anhydrous crystal form thereof.

8. Form F of seletalisib as claimed in claim 6, having an XRPD pattern that exhibits characteristic peaks at 6.4° , 8.7° , 15.2° , 15.5° , and 20.3° $2\theta \pm 0.2^\circ$ 2θ using Cu K α radiation.


5 9. Form F of seletalisib as claimed in claim 7 or claim 8, that exhibits a melting endotherm at $238.5^\circ\text{C} \pm 5^\circ\text{C}$ in the DSC thermogram.

10. A process for the preparation of Form F of seletalisib, which comprises reacting the compound of formula (II) with a compound of formula (III):

10



(II)



(III)

wherein L¹ represents C₁₋₆ alkoxy, optionally substituted aryloxy, optionally substituted arylthio or optionally substituted heteroaryl; under anhydrous conditions.

15

11. A process as claimed in claim 10, wherein L¹ represents methoxy, ethoxy, *n*-propoxy, *n*-butoxy, isobutoxy, phenoxy, pentafluorophenoxy, 4-chlorophenoxy, 4-nitrophenoxy, 4-methylphenoxy, 2,4,6-trimethylphenoxy, 4-methoxyphenoxy, phenylthio, imidazol-1-yl, 1,2,4-triazol-1-yl or 4-(dimethylamino)pyridinium-1-yl.

20

12. A process as claimed in claim 11, wherein L¹ represents ethoxy.

13. A process for the preparation of Form B of seletalisib, which comprises contacting Form F of seletalisib with water in an organic solvent; followed by crystallization therefrom.

25

14. A process for the preparation of Form F of seletalisib, which comprises contacting Form B of seletalisib with a water-free medium; followed by crystallization therefrom.

5 15. A pharmaceutical composition comprising Form B or Form F of seletalisib as defined in any one of claims 1 to 9 in association with a pharmaceutically acceptable carrier.

10 16. Form B or Form F of seletalisib as defined in any one of claims 1 to 9 for use in therapy.

15 17. Form B or Form F of seletalisib as defined in any one of claims 1 to 9 for use in the treatment and/or prevention of a disorder for which the administration of a selective PI3K inhibitor is indicated.

18. The use of Form B or Form F of seletalisib as defined in any one of claims 1 to 9 for the manufacture of a medicament for the treatment and/or prevention of a disorder for which the administration of a selective PI3K inhibitor is indicated.

20 19. A method for the treatment and/or prevention of a disorder for which the administration of a selective PI3K inhibitor is indicated which comprises administering to a patient in need of such treatment an effective amount of Form B or Form F of seletalisib as defined in any one of claims 1 to 9.

25